Robert Duggan: Kevin, I’ll take that. I’ve known Dr. Hollingsworth for quite a while. He’s an outstanding scientist and doctor in his own right and kind of grew up with us at Computer Motion. So he’s familiar with a lot of these things. But I would say we’re very much different than a battery. We are a tunable device that can scale, shift and adjust as needed and appropriate energy and place it in a very pinpointed area. It’d be like comparing a battery to a radio. It’s €“ there are some similarities, but it’s clearly not identical and the similarities are reasonably few. In terms of the application in dermatology, we had some spectacular results in dermatology. We had no adverse events, no reportable events to the FDA. Patients walked out of the facility with the potential to have a cleared lesion that went well beyond what normal treatments could provide to them.
So you might say, well, it appeared to fail because you weren’t able to generate the revenues. What happened is over 6,000 patients were treated, treated well, treated effective. The device proved its workability. It’s still the only device of its kind of that nature in that business. It just was not viable in terms of €“ relative to the other procedures that were being performed is like you could come in with a slice in your arm and either they could put a band-aid on it or suture it, and the band-aid is so less expensive than the suture that they put the bandage on. We really got a lot of plot. It’s well deserved from patients and physicians and dermatologists alike from that field. So that product succeeded. Our business plan did not succeed.
And we’ll take our own hit for that. We thought there would be a faster assimilation of the product, a stronger uptake, and we could crossover into the world of viability. And while things were improving as we moved along, we did have other alternatives, and as you know, from many companies that I’ve started and work with, the first few words are to build a viable, those first four words, which means that you can create sustainable future out of what you really do, and you’re not dependent on outside funding and financing. So with that in mind, we had to pivot and we did, and we pivot over to an area that has benefited greatly from an FDA-approved device has benefited greatly from the viewpoint and the knowledge the confidence that this device can work, can deliver energy of high volume at high speed and do so.
And go right to the cellular aspect of a tissue that is needed in repair and not hit acellular structures. So when you’re dealing with the heart, that becomes critically important. So we’re taking a win on the derm, but we’ve got an order of magnitude, larger opportunity. We’ve got a product very specific to that. And we’re really ready to go here. So, I hope that addresses the question. I appreciate the question, too.
Kevin Danahy: Thank you, Bob. Appreciate that.
James Hollingsworth: Thanks Bob.
Trip Taylor: Operator, next question.
Operator: Our next question comes from the line of Private Investor. Please go ahead.
Unidentified Analyst: Hey guys. Hi friends.
Kevin Danahy: Hey, Andy. How are you doing?
Unidentified Analyst: I’m good. I really, I have two questions. One is there any possibility on the breakthrough you had on basal cell carcinoma. Can that be license also given to other entity to take it further or get pay back some money on it? No, we just
Kevin Danahy: Yes. I’ll jump in, and then if Darrin or Bob want to jump in. Right now, as we mentioned in our last call, we are exploring all opportunities with derm, as Bob just said very well that we were very proud of the results that that we got from our system. Right now, it’s just a matter of the commercialization architecture that we didn’t have in place to support that. Now the companies might have that, that we’re exploring, and we’re continuing to talk with. So we’re excited to continue to look at that.
